Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid Tumors

Daniel Carrizosa, MD, MS, oncologist, Head and Neck Cancer Lung Cancer, Hematology and Medical Oncology (Cancer), Atrium Health Levine Cancer Institute (Thoracic-Pulmonary), discusses the efficacy findings from the phase 2 CRESTONE trial (NCT04383210) in patients with NRG1 fusion–positive, advanced solid tumors.

The phase 2, open-label, international trial evaluated seribantumab in patients with recurrent, locally advanced and/or metastatic solid tumors that harbor NRG1 fusions.

Data presented during the 2022 Annual ASCO Meeting showed that seribantumab displayed favorable efficacy and safety, Carrizosa says. As of April 2022, the investigator-assessed overall response rate (ORR) achieved with the agent was 33%, with a disease control rate of 92% among 12 evaluable patients, Carrizosa explains. Notably, most patients enrolled to the trial had NRG1 fusion–positive non–small cell lung cancer, and this subgroup experienced an ORR of 36% with the agent, Carrizosa adds.

Among all patients, there were 2 partial responses and 2 complete responses, showcasing that seribantumab has antitumor activity in patients with NRG1 fusions, Carrizosa concludes.